Table 2.
Therapies According to Outcomes at 1‐Year Follow‐Up
| Therapies | No Cardiovascular Death (n=739) | Cardiovascular Death (n=75) | P Value |
|---|---|---|---|
| Revascularization | |||
| Coronary angiography | 682 (92) | 60 (80) | 0.001 |
| CABG | 30 (4) | 0 (0) | 0.077 |
| PCI | 419 (57) | 31 (41) | 0.015 |
| <48 h | |||
| β Blockers | 521 (71) | 48 (64) | 0.313 |
| ACE inhibitors or ARBs | 362 (49) | 40 (53) | 0.406 |
| Diuretics | 304 (41) | 51 (68) | <0.001 |
| Aspirin | 714 (97) | 71 (95) | 0.763 |
| P2Y12 receptor antagonists | 680 (92) | 65 (87) | 0.216 |
| Statins | 674 (91) | 63 (84) | 0.087 |
| At discharge | |||
| β Blockers | 640 (87) | 58 (77) | 0.053 |
| ACE inhibitors or ARBs | 560 (76) | 46 (61) | 0.010 |
| Diuretics | 254 (34) | 42 (56) | <0.001 |
| Aspirin | 673 (91) | 64 (85) | 0.197 |
| P2Y12 receptor antagonists | 484 (65) | 43 (57) | 0.205 |
| Statins | 665 (90) | 67 (89) | 0.879 |
Data are given as number (percentage). ACE indicates angiotensin‐converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.